Courier Capital LLC increased its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 6.7% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 54,890 shares of the biopharmaceutical company’s stock after purchasing an additional 3,432 shares during the period. Courier Capital LLC’s holdings in Bristol-Myers Squibb were worth $3,408,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of BMY. Sciencast Management LP purchased a new stake in Bristol-Myers Squibb during the 1st quarter worth about $602,000. WealthPLAN Partners LLC lifted its holdings in Bristol-Myers Squibb by 240.9% during the 1st quarter. WealthPLAN Partners LLC now owns 20,040 shares of the biopharmaceutical company’s stock worth $1,268,000 after purchasing an additional 14,161 shares in the last quarter. Nexthera Capital LP lifted its holdings in Bristol-Myers Squibb by 15.8% during the 1st quarter. Nexthera Capital LP now owns 342,399 shares of the biopharmaceutical company’s stock worth $21,657,000 after purchasing an additional 46,799 shares in the last quarter. Garde Capital Inc. purchased a new stake in Bristol-Myers Squibb during the 1st quarter worth about $305,000. Finally, Private Capital Group LLC lifted its holdings in Bristol-Myers Squibb by 41.0% during the 1st quarter. Private Capital Group LLC now owns 11,052 shares of the biopharmaceutical company’s stock worth $699,000 after purchasing an additional 3,214 shares in the last quarter. 72.28% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bristol-Myers Squibb stock opened at $57.51 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.28 and a current ratio of 1.40. The stock has a market cap of $101.47 billion, a PE ratio of 19.11, a PEG ratio of 1.70 and a beta of 0.98. Bristol-Myers Squibb Co has a 12 month low of $49.96 and a 12 month high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.87 by $0.14. The firm had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.48 billion. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The company’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.74 EPS. Research analysts forecast that Bristol-Myers Squibb Co will post 3.62 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 1st. Stockholders of record on Friday, October 5th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, October 4th. This represents a $1.60 annualized dividend and a dividend yield of 2.78%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 53.16%.
BMY has been the topic of several recent analyst reports. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 price target on the stock in a report on Friday, October 5th. Guggenheim initiated coverage on Bristol-Myers Squibb in a report on Monday, October 8th. They issued a “neutral” rating on the stock. JPMorgan Chase & Co. raised their price target on Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an “overweight” rating in a report on Monday, October 8th. BMO Capital Markets raised their price target on Bristol-Myers Squibb from $47.00 to $51.00 and gave the company a “market perform” rating in a report on Monday, July 23rd. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $67.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, July 31st. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $62.95.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.